Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy

Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy

Chronic kidney disease is a major complication of Fabry disease. Podocytes accumulate globotriaosylceramide inclusions more than other kidney cell types in Fabry patients. Podocyte injury occurs early in age, and is progressive. Since injured podocytes detach into the urine (podocyturia), we hypothe...

Full description

Bibliographic Details
Main Authors:	Fall, Brent, Scott, C. Ronald, Mauer, Michael, Shankland, Stuart, Pippin, Jeffrey, Jefferson, Jonathan A., Wallace, Eric, Warnock, David, Najafian, Behzad
Format:	Online
Language:	English
Published:	Public Library of Science 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161377/

Similar Items

Mosaicism of Podocyte Involvement Is Related to Podocyte Injury in Females with Fabry Disease
by: Mauer, Michael, et al.
Published: (2014)

One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease
by: Najafian, Behzad, et al.
Published: (2016)

Dysregulated Autophagy Contributes to Podocyte Damage in Fabry’s Disease
by: Liebau, Max C., et al.
Published: (2013)

Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease
by: Fervenza, Fernando C, et al.
Published: (2008)

Fabry nephropathy: a review – how can we optimize the management of Fabry nephropathy?
by: Waldek, Stephen, et al.
Published: (2014)

The coincidence of IgA nephropathy and Fabry disease
by: Maixnerová, Dita, et al.
Published: (2013)

Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy
by: Morrissey, Ryan P, et al.
Published: (2011)

Receptor-Mediated Endocytosis of α-Galactosidase A in Human Podocytes in Fabry Disease
by: Prabakaran, Thaneas, et al.
Published: (2011)

Fabry Cardiomyopathy
by: Yoon, Jae Yong, et al.
Published: (2013)

Fabry′s disease
by: Laxmikant Ramkumarsingh Tomar, et al.
Published: (2015-01-01)

Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry
by: Ortiz, Alberto, et al.
Published: (2016)

Characterization of vertigo and hearing loss in patients with Fabry disease
by: Maria Köping, et al.
Published: (2018-08-01)

Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones
by: Cammisa, Marco, et al.
Published: (2013)

Coincidental finding of Fabry’s disease in a patient with IgA nephropathy
by: Kakita, Tomoko, et al.
Published: (2010)

Fabry Disease and Early Stroke
by: Feldt-Rasmussen, U.
Published: (2011)

Endoscopic images in Fabry disease
by: Kouvaras, Stergios N.
Published: (2012)

Fabry disease and incidence of cancer
by: Sarah Bird, et al.
Published: (2017-09-01)

ACE-inhibition increases podocyte number in experimental glomerular disease independent of proliferation
by: Zhang, Jiong, et al.
Published: (2014)

Increased urinary CD80 excretion and podocyturia in Fabry disease
by: Trimarchi, H., et al.
Published: (2016)

Fabry Disease Diagnosed Based on the Detection of Urinary Mulberry Bodies
by: Honda, Tomoko, et al.
Published: (2016)

Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy
by: Warnock, David G, et al.
Published: (2015)

Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy
by: Jefferson Loso, et al.
Published: (2018-08-01)

Pharmacological chaperone therapy for Fabry disease
by: ISHII, Satoshi
Published: (2012)

The distribution of hypertrophy in anderson fabry disease
by: Sado, Daniel M, et al.
Published: (2011)

Aortic arch stiffness in Fabry disease
by: Bensalah, Zoubir M, et al.
Published: (2013)

ANDERSON-FABRY DISEASE: MANIFESTATION AND PROGNOSIS
by: N. O. Pichkur
Published: (2017-12-01)

Podocitúria na doença de Fabry
by: Ester Miranda Pereira, et al.
Published: (2016-03-01)

Electrocardiographic Changes and Arrhythmia in Fabry Disease
by: Namdar, Mehdi
Published: (2016)

Gastrointestinal Symptoms of Patients with Fabry Disease
by: Pensabene, Licia, et al.
Published: (2016)

Transformation optics with Fabry-Pérot resonances
by: Sadeghi, M. M., et al.
Published: (2015)

The phenotypes of podocytes and parietal epithelial cells may overlap in diabetic nephropathy
by: Andeen, Nicole K., et al.
Published: (2015)

Glomerular parietal epithelial cells contribute to adult podocyte regeneration in experimental focal segmental glomerulosclerosis
by: Eng, Diana G., et al.
Published: (2015)

Fabry disease presenting with sudden hearing loss and otosclerosis: a case report
by: Felisati, Giovanni, et al.
Published: (2012)

Fibrosis: a key feature of Fabry disease with potential therapeutic implications
by: Weidemann, Frank, et al.
Published: (2013)

Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb3) in Fabry Transgenic Mice and in the Plasma of Fabry Patients
by: Young-Gqamana, Brandy, et al.
Published: (2013)

Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ)
by: Ramaswami, Uma, et al.
Published: (2012)

Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey
by: Barba-Romero, Miguel-Ángel, et al.
Published: (2016)

FAbry STabilization indEX (FASTEX): an innovative tool for the assessment of clinical stabilization in Fabry disease
by: Mignani, Renzo, et al.
Published: (2016)

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
by: Beck, Michael, et al.
Published: (2015)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
by: Biegstraaten, Marieke, et al.
Published: (2015)